EREG (D4O5I) Rabbit mAb

• 产品编号：CST-12048S      品牌：CST       原厂货号：12048S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

EREG (D4O5I)兔单抗能够识别内源性水平的总EREG蛋白。该单克隆抗体是通过用合成肽免疫动物而制备的，该合成肽是人EREG蛋白Glu155附近的残基。表皮调节素（EREG）属于表皮生长因子（EGF）家族，是表皮生长因子受体（EGFR）和ErbB4的配体（1-3）。 EREG同源二聚体以及含有表皮生长因子受体或者ErbB4异源二聚体的结合，导致受体激活和下游信号促进细胞生长和增殖（4-6）。在正常人组织中，在胎盘和外周血巨噬细胞中，EREG中等水平表达。调查研究表明，EREG在许多肿瘤细胞系中高水平表达，并且EREG的表达与原发性癌症侵袭和转移有关（7-11）。除了其参与肿瘤发生过程，EREG的变体也显示出与易感性结核病有关（12）。EREG作为多个条带迁移，包括一个〜30kDa的糖基化膜结合形式(proepiregulin)，一个19 kDa的非糖基化肽形式和一个17 kDa的成熟形式（13）。

1. Olayioye, M.A. et al. (2000) EMBO J 19, 3159-67.
2. Shelly, M. et al. (1998) J Biol Chem 273, 10496-505.
3. Komurasaki, T. et al. (1997) Oncogene 15, 2841-8.
4. Komurasaki, T. et al. (2002) Growth Factors 20, 61-9.
5. Shirakata, Y. et al. (2000) J Biol Chem 275, 5748-53.
6. Toyoda, H. et al. (1995) J Biol Chem 270, 7495-500.
7. Toyoda, H. et al. (1997) Biochem J 326 ( Pt 1), 69-75.
8. Zhu, Z. et al. (2000) Biochem Biophys Res Commun 273, 1019-24.
9. Kuramochi, H. et al. (2012) BMC Cancer 12, 88.
10. Zhang, J. et al. (2008) Cancer Prev Res (Phila) 1, 201-7.
11. Sunaga, N. et al. (2012) Oncogene , .
12. Thuong, N.T. et al. (2012) Genes Immun 13, 275-81.
13. Baba, I. et al. (2000) Cancer Res 60, 6886-9.

原厂资料：

Specificity / Sensitivity

EREG (D4O5I) Rabbit mAb recognizes endogenous levels of total EREG protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu155 of human EREG protein.

Background

Epiregulin (EREG) belongs to the epidermal growth factor (EGF) family and is a ligand for the EGF receptor (EGFR) and ErbB4 (1-3). The binding of EREG to homodimers, as well as heterodimers containing EGFR or ErbB4, leads to receptor activation and downstream signaling to promote cell growth and proliferation (4-6). In normal human tissue, moderate levels of EREG are expressed in the placenta and peripheral blood macrophages. Research studies have shown that EREG is expressed at high levels in numerous cancer cell lines, and EREG expression is correlated with primary cancer aggresiveness/metastases (7-11). In addition to its involvement in tumorigenesis, a variant of EREG has also been shown to be associated with tuberculosis susceptibility (12). EREG migrates as multiple bands including a ~30 kDa glycosylated membrane bound form (proepiregulin), a 19 kDa nonglycosylated propeptide form, and a 17 kDa mature form (13).

1. Olayioye, M.A. et al. (2000) EMBO J 19, 3159-67.
2. Shelly, M. et al. (1998) J Biol Chem 273, 10496-505.
3. Komurasaki, T. et al. (1997) Oncogene 15, 2841-8.
4. Komurasaki, T. et al. (2002) Growth Factors 20, 61-9.
5. Shirakata, Y. et al. (2000) J Biol Chem 275, 5748-53.
6. Toyoda, H. et al. (1995) J Biol Chem 270, 7495-500.
7. Toyoda, H. et al. (1997) Biochem J 326 ( Pt 1), 69-75.
8. Zhu, Z. et al. (2000) Biochem Biophys Res Commun 273, 1019-24.
9. Kuramochi, H. et al. (2012) BMC Cancer 12, 88.
10. Zhang, J. et al. (2008) Cancer Prev Res (Phila) 1, 201-7.
11. Sunaga, N. et al. (2012) Oncogene , .
12. Thuong, N.T. et al. (2012) Genes Immun 13, 275-81.
13. Baba, I. et al. (2000) Cancer Res 60, 6886-9.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.